Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
US11365257B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 20, 2017 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Oct 7, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.